

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

20 August 2020 (20.08.2020)



(10) International Publication Number

WO 2020/168090 A1

(51) International Patent Classification:

C07K 14/705 (2006.01) A61K 39/00 (2006.01)

C07K 14/725 (2006.01) C07K 19/00 (2006.01)

C12N 5/0783 (2010.01) A61P 35/02 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2020/018127

(22) International Filing Date:

13 February 2020 (13.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/805,052 13 February 2019 (13.02.2019) US

(72) Inventors; and

(71) Applicants: **GEERLINGS, Maurits, W.** [NL/US]; 1055 Westlakes Drive, 3rd Floor, Berwyn, PA 19312 (US). **BIONDI, Andrea** [IT/IT]; Pergolesi, 33, 20900 Monza (MB) (IT). **RAMBALDI, Alessandro** [IT/IT]; Piazzza OMS, 1, 24127 Bergamo (IT). **DASTOLI, Giuseppe** [IT/IT]; Pergolesi, 33, 20900 Monza (MB) (IT).

(74) Agent: **PUGH, Alyssa, R.M.** et al.; Morgan Lewis & Bockius LLP, 1701 Market Street, Philadelphia, PA 19103-2921 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CANCER IMMUNOTHERAPY USING COMBINATIONS OF CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND MONOCLONAL ANTIBODIES

(57) Abstract: Methods of increasing or enhancing the efficacy of CAR B cell malignancy treatment regimens using immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) engineered to express chimeric antigen receptors (CAR(s)) that target malignant B cells in combination with antibodies (e.g., monoclonal antibodies, antibody-drug conjugates) that target malignant B cells are provided. Also provided are methods of treating a B cell malignancy in a subject comprising administering to the subject a CAR B cell malignancy treatment regimen and an antibody that targets malignant B cells.



WO 2020/168090 A1

TITLE OF THE INVENTION

[0001] CANCER IMMUNOTHERAPY USING COMBINATIONS OF CELLS EXPRESSING
CHIMERIC ANTIGEN RECEPTORS AND MONOCLONAL ANTIBODIES

CROSS-REFERENCE TO RELATED APPLICATIONS

5 **[0002]** This application claims the benefit of U.S. Provisional Patent Application No. 62/805,052 filed February 13, 2019 entitled “Cancer Immunotherapy Using Combinations of Cells Expressing Chimeric Antigen Receptors and Monoclonal Antibodies”, which is incorporated by reference herein in its entirety and for all purposes.

FIELD OF THE INVENTION

10 **[0003]** The present disclosure relates generally to the use of immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) engineered to express chimeric antigen receptors (CAR(s)) that target malignant B cells in combination with antibodies (e.g., monoclonal antibodies, antibody-drug conjugates) that target malignant B cells to treat B cell malignancies.

BACKGROUND OF THE INVENTION

15 **[0004]** Immunotherapy is a promising approach for the treatment of cancer. Immunotherapy with cells expressing chimeric antigen receptors (CARs) that target antigens expressed by the tumor has the advantage of targeted therapies that can invoke a rapid and sustained immune response against a cancer. CAR therapy has shown promising results in the clinic in treating some
20 hematological cancers, such as B cell malignancies (see, e.g., Novartis (2017) Prescribing Information for FDA approved products Kymriah™ and Yescarta™ incorporated by reference herein in their entirety). For an overview of CAR constructs, CAR therapy and CAR toxicities, see, X. Han, et al., Chronic Diseases and Translational Medicine 4 (2018) 225-243; and Tariq S, Haider S Ali, Hasan M, et al. (October 23, 2018) Chimeric Antigen Receptor T-Cell Therapy: A Beacon of
25 Hope in the Fight Against Cancer. Cureus 10(10). Combinations of CAR-T cells with antibodies that block the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or the programmed death-1 (PD-1) receptor or the PD-L1 ligand has been suggested to prolong the effector function of CAR-T cells at sites of solid tumors (Gianpietro Dotti, Stephen Gottschalk, Barbara Savoldo and Malcolm K, Brenner Immunol Rev. 2014 January; 257(1); and XU, et al., Oncology Letters 16: 2063-2070,
30 2018) .

[0005] However, there exists a need for therapies that enhance the efficacy of CAR therapies and/or to treat B cell malignancies, as a significant number of patients receiving CAR therapies either relapse or remain refractory following such therapies.

BRIEF SUMMARY OF THE INVENTION

- 5 [0006] The present invention is based, at least in part, upon an unexpected and surprising clinical outcome resulting from the consecutive administration of two therapeutic drugs, each having distinctive mechanisms of action. The first drug regarded a chimeric antigen receptor-modified T cell immunotherapy. The second drug regarded an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (see Example section for further details).
- 10 [0007] Accordingly, the present invention concerns, at least in part, methods for treating a disease associated with expression of a tumor antigen, for example, a B cell malignancy, in a subject by administering to the subject a combination of a CAR immunotherapy and an antibody, for example an antibody-drug conjugate.
- [0008] In one aspect, the invention includes a method of increasing or enhancing the efficacy of a CAR B cell malignancy treatment regimen in a subject comprising administering to the subject a CAR immunotherapy that targets malignant B cells and an antibody that targets malignant B cells.
- 15 [0009] In another aspect the invention includes a method of treating a B cell malignancy in a subject comprising administering to the subject a CAR B cell malignancy treatment regimen and an antibody that targets malignant B cells.
- 20 [0010] In other embodiments of any of the methods described herein, the antigen binding domain of the CAR molecule targets (e.g., binds to) a tumor antigen that is associated with a B cell malignancy, e.g., expressed by a malignant B cell. In some embodiments, the tumor antigen is present in a disease chosen from a leukemia or a lymphoma.

DETAILED DESCRIPTION OF THE INVENTION

25 Definitions

- [0011] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, suitable methods and materials are described below. All
- 30 publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety. In cases of conflict, the present specification, including

definitions, will control. In addition, the materials, methods, and examples described herein are illustrative only and are not intended to be limiting.

[0012] As used herein, the singular form “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. For example, reference to “a cell” includes a plurality of such cells and reference to “an antibody” includes a plurality of such antibody.

[0013] The term “B cell antigen” refers to a molecule that is preferentially expressed on the surface of a B cell which can be targeted with an agent which binds thereto. The B cell antigen of particular interest is preferentially expressed on malignant B cells compared to other non-malignant B cells or non-B cells of a mammal. Examples of B cell antigens include CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD34, CD37, CD38, CD53, CD72, CD73, CD74, CD75, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD123, CD179b, ROR1, BCMA, and FLT3.

[0014] As used herein, a “B cell malignancy” refers to all types of B cell malignancies found in mammals and known in the art, including, but not limited to solid tumors and hematological cancers.

[0015] As used herein, “hematological cancer” refers to all types of hematological cancer and hematopoietic tumors, neoplasm or malignant tumors found in mammals, including, but not limited to leukemias and lymphomas. Examples include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoid Leukemia (“B-ALL”), T-cell Acute Lymphoid Leukemia (“T-ALL”), Acute Lymphoblastic Leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., Chronic Myelogenous Leukemia (CML), Chronic Lymphoid Leukemia (CLL), or other hematological malignancies.

[0016] Administered “in combination”, as used herein, means that two (or more) different treatments are administered to the subject during the course of the subject's affliction with the disorder, e.g., the two or more treatments are administered after the subject has been diagnosed with the disorder and before the disorder has been cured or eliminated or treatment has ceased for other reasons. In some embodiments, the administration of one treatment is still occurring when the administration of the second begins, so that there is overlap in terms of administration. This is sometimes referred to herein as “simultaneous” or “concurrent” administration. In other embodiments, the administration of one treatment ends before the administration of the other treatment begins. In some embodiments of either case, the treatment is more effective because of combined administration and results in an unexpectedly superior effect compared to the effect obtained with the individual treatments. For example, the first or second treatment is more effective,

e.g., an increased or enhanced effect of the first treatment is seen after the second treatment or an equivalent effect is seen with less of the first treatment, than would be seen if the first treatment were administered in the absence of the second treatment, or the analogous situation is seen with the second treatment. In some embodiments, administration is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment administered in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive (i.e., synergistic). The administration can be such that an effect of the first treatment administered is still detectable when the second is administered.

[0017] The term "Chimeric Antigen Receptor" or alternatively "CAR(s)" refers to a recombinant polypeptide construct comprising at least an extracellular antigen binding domain, a transmembrane domain and a cytoplasmic signaling domain (also referred to herein as an "intracellular signaling domain," a cytoplasmic signaling domain" or a "stimulatory molecule") comprising a functional signaling domain derived from a stimulatory molecule. The terms "Chimeric Antigen Receptor" and "CAR" include CARs that are generally known in the art (see, e.g., Shi et al., Molecular Cancer 2014, 13:219, which is incorporated herein in its entirety).

[0018] The cytoplasmic signaling domain can comprise a primary signaling domain (e.g., a primary signaling domain of CD3-zeta). The cytoplasmic signaling domain can further comprise one or more functional signaling domains derived from at least one costimulatory molecule. The costimulatory molecule is chosen from 4-1BB (i.e., CD137), CD27, ICOS, and/or CD28.

[0019] A CAR that comprises an antigen binding domain (e.g., a single chain variable fragment of a monoclonal antibody ("scFv")) that targets, e.g., binds to, a specific antigen X, such as those described herein, is also referred to as X CAR. For example, a CAR that comprises an antigen binding domain that targets CD19 is referred to as CD19 CAR. A CAR that comprises an antigen binding domain (e.g., a scFv) that targets a specific tumor antigen (TA) is also referred to as TA CAR. A CAR that comprises an antigen binding domain (e.g., a scFv) that targets a specific B cell antigen (BCA) is also referred to as BCA CAR.

[0020] The terms "CAR immunotherapy cancer treatment that targets malignant B cells" and "CAR B cell malignancy treatment regimen" and the like refer to treatment of a subject with immune cells (e.g., T cells, NK cells, CIK cells, macrophages) that have been genetically engineered to express chimeric antigen receptors (CARs) and specifically target one or more tumor-specific receptors of malignant B cells. CAR immunotherapy is generally known in the art (see, e.g., Shi et al., Molecular Cancer 2014, 13:219, which is incorporated herein in its entirety).

[0021] The CAR construct can be introduced into immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) using viral or non-viral techniques known in the art.

[0022] The term "antibody," as used herein, refers to a protein, or polypeptide sequence derived from an immunoglobulin molecule which specifically binds with an antigen. Antibodies can be polyclonal or monoclonal, multiple or single chain, or intact immunoglobulins, and may be derived from natural sources or from recombinant sources. Antibodies can be tetramers of immunoglobulin molecules. The term "antibody" includes functional antibody fragments, including e.g., Fab', F(ab')₂, Fab, Fv, and scFv fragments. Antibodies can be humanized, human, and/or antibody drug-conjugates. The term "antibody" includes antibodies that are generally known in the art.

[0023] As used herein, the term "effective amount," "safe and effective amount" or "therapeutically effective amount" and the like refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. For example, an amount effective to increase or enhance the efficacy of a treatment, delay the growth of or to cause a cancer to shrink or reduce malignant cell count in peripheral blood, bone marrow and/or other organs. The specific safe and effective amount or therapeutically effective amount will vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal or animal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds (i.e., immune effector cells and/or antibodies).

[0024] As used herein, the term "enhancing the effect" or "increasing the effect" refers to reducing the population of cancer cells. The quantity, number, amount or percentage of cancer cells can be reduced by at least 25%, at least 30%, at least 40%, at least 50%, at least 65%, at least 75%, at least 85%, at least 95%, or at least 99% relative to a negative control.

[0025] As used herein, the terms "treat", "treatment", and "treating" refer to the reduction or amelioration of the progression, severity and/or duration of a cancer or proliferative disorder, or the amelioration of one or more symptoms (preferably, one or more discernible symptoms) of a cancer or proliferative disorder resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as a CAR and antibody of the invention). In specific embodiments, the terms "treat", "treatment" and "treating" refer to the amelioration of at least one measurable physical parameter of a proliferative disorder, such as growth of a tumor, not necessarily discernible by the patient. In other embodiments the terms "treat", "treatment" and "treating" refer to the inhibition of the progression of a cancer or proliferative disorder, either physically by, e.g., stabilization of a

discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both. In other embodiments the terms "treat", "treatment" and "treating" refer to the reduction or stabilization of tumor size or cancerous cell count.

[0026] Thus, treating may include enhancing or increasing efficacy, suppressing, inhibiting, preventing, treating, or a combination thereof. Treating refers inter alia to increasing time to disease progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to alternative therapeutics, or a combination thereof. "Suppressing" or "inhibiting", refers inter alia to delaying the onset of tumor associated symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, reducing the severity of symptoms, reducing the severity of an acute episode, reducing the number of symptoms, reducing the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, prolonging patient survival, or a combination thereof. The symptoms can be primary or secondary. "Primary" refers to a symptom that is a direct result of the proliferative disorder (e.g., cancer), while, secondary refers to a symptom that is derived from or consequent to a primary cause.

[0027] The term "subject" is intended to include living organisms (e.g., mammals, human).

[0028] "Relapsed" or "relapse" as used herein refers to the return or reappearance of a disease (e.g., cancer) or the signs and symptoms of a disease such as cancer after a period of improvement or responsiveness, e.g., after prior treatment of a therapy, e.g., cancer therapy. The initial period of responsiveness may involve the level of cancer cells falling below a certain threshold, e.g., below 20%, 10%, 5%, 4%, 3%, 2%, or 1%. The reappearance may involve the level of cancer cells rising above a certain threshold, e.g., above 20%, 1%, 10%, 5%, 4%, 3%, 2%, or 1%. For example, in the context of ALL, the reappearance may involve, e.g., a reappearance of blasts in the blood, bone marrow (> 5%), or any extramedullary site, after a complete response. A complete response, in this context, may involve < 5% bone marrow blasts. More generally, in an embodiment, a response (e.g., complete response or partial response) can involve the absence of detectable MRD (minimal residual disease). In an embodiment, the initial period of responsiveness lasts at least 1, 2, 3, 4, 5, or 6 days; at least 1, 2, 3, or 4 weeks; at least 1, 2, 3, 4, 6, 8, 10, or 12 months; or at least 1, 2, 3, 4, or 5 years.

Description

[0029] The present invention is based in part upon the surprising discovery that a CAR immunotherapy cancer treatment regimen that targets malignant B cells in combination with

administration of an antibody that targets B cells resulted in a greater therapeutic effect compared to the use of the CAR treatment alone.

[0030] Accordingly, the present invention provides methods of increasing or enhancing the efficacy of a CAR immunotherapy cancer treatment that targets malignant B cells in a subject in need thereof comprising administering to the subject an antibody that targets malignant B cells in combination with the CAR immunotherapy. Preferably, the cancer is a B cell malignancy. More preferably the B cell malignancy is a hematological cancer. Preferably, the CAR immunotherapy comprises immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) engineered to express a TA CAR or a BCA CAR. Preferably, the immune effector cells target a CD19 tumor antigen. Preferably, the antibody that targets malignant B cells is a humanized or human monoclonal antibody. Preferably the antibody that targets malignant B cells is a humanized or human monoclonal antibody that targets a CD22 tumor antigen.

[0031] Additionally, the present invention includes a method of treating a cancer in a subject in need thereof comprising administering to the subject an antibody that targets malignant B cells in combination with a CAR immunotherapy cancer treatment that targets malignant B cells. Preferably the cancer is a B cell malignancy. More preferably, the B cell malignancy is a hematologic cancer. Preferably, the CAR immunotherapy comprises immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) engineered to express a TA CAR or a BCA CAR. Preferably, the immune effector cells target a CD19 tumor antigen. Preferably, the antibody that targets malignant B cells is a humanized or human monoclonal antibody. Preferably the antibody that targets malignant B cells is a humanized or human monoclonal antibody that targets a CD22 tumor antigen.

[0032] The present invention also provides methods of reducing or eliminating existing tumor burden, reducing tumor volume, stimulating tumor regression, preventing relapse or increasing overall survival in a subject in need thereof comprising administering to the subject an antibody that targets malignant B cells in combination with a CAR immunotherapy cancer treatment that targets malignant B cells.

[0033] In embodiments wherein the immune effector cells are administered to a subject in combination with an antibody that targets malignant B cells, the subject may achieve one or more of the following: 1) increased tolerance to the immune effector cells; 2) increased efficacy of the immune effector cells; 3) reduced likelihood of rejection of the immune effector cells; and/or 4) increased or reduced adverse response that may be caused by the immune effector cells. Thus, the methods provided herein feature methods that result in increasing or enhancing the therapeutic

efficacy of the immune effector cell therapy and/or the antibody therapy for treating a disease associated with the expression of a tumor antigen, e.g., a cancer described herein.

Immune Effector Cells

5 **[0034]** In one embodiment, the present invention provides immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) that are engineered to contain one or more CARs that direct the immune effector cells to a malignant B cell. This is achieved through an antigen binding domain on the CAR that is specific for a malignant B cell antigen.

10 **[0035]** In an embodiment, the B cell antigen is an antigen that is expressed on the surface of the malignant B cell. The antigen can be expressed on the surface of any one of the following types of B cells: progenitor B cells (e.g., pre-B cells or pro-B cells), early pro-B cells, late pro-B cells, large pre-B cells, small pre-B cells, immature B cells, e.g., naive B cells, mature B cells, plasma B cells, plasmablasts, memory B cells, B-1 cells, B-2 cells, marginal-zone B cells, follicular B cells, germinal center B cells, or regulatory B cells (Bregs).

15 **[0036]** The present invention encompasses immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) comprising a recombinant nucleic acid construct comprising sequences encoding a CAR, e.g., a CAR molecule that binds to a tumor antigen (e.g., a TA CAR) or a CAR molecule that binds to a malignant B cell antigen (e.g., a BCA CAR), wherein the CAR comprises an antigen binding domain (e.g., antibody or antibody fragment) that binds specifically to a tumor
20 antigen or a malignant B cell antigen.

25 **[0037]** Preferably, the antigen binding domain of the immune effector cells, e.g., a CAR molecule expressed by T cells, NK cells, CIK cells, or macrophages targets (e.g., binds to) a tumor antigen that is associated with a B cell malignancy, e.g., expressed by a B cell malignancy, preferably a hematological cancer.

30 **[0038]** In preferred embodiments, the tumor antigen that is targeted by the immune effector cells is present in a hematological cancer chosen from a leukemia or a lymphoma. Preferably, leukemias include, but are not limited to e.g., B-cell Acute Lymphoid Leukemia ("B-ALL"), T-cell Acute Lymphoid Leukemia ("T-ALL"), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Chronic Lymphoid Leukemia (CLL). Preferably, the leukemia is a relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia. Preferably, lymphomas include, but are not limited to Hodgkin's Disease, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade

B-cell lymphoma and DLBCL arising from follicular lymphoma. Preferably, the lymphoma is a relapsed or refractory B-cell lymphoma.

[0039] The present invention provides CARs that can target the following exemplary B cell antigens including but not limited to: CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD34, CD37, CD38, CD53, CD72, CD73, CD74, CD75, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD123, CD179b, ROR1, BCMA, and FLT3.

[0040] In a preferred embodiment, the CAR targets (e.g., binds to) CD19. More preferably, the immune effector cells that are engineered to contain one or more CARs that direct the immune effector cells to a malignant B cell are CD19-directed genetically modified autologous T-cells (e.g., tisagenlecleucel, axicabtagene ciloleucel) or CIK cells.

Antibodies That Target malignant B cells

[0041] The antibodies that target (e.g., bind to) malignant B cells target a tumor antigen that is associated with a B cell malignancy, e.g., expressed by a B cell malignancy, preferably a hematological cancer.

[0042] In preferred embodiments, the tumor antigen that is targeted by the antibodies is present in a hematological cancer chosen from a leukemia or a lymphoma. Preferably, leukemias include, but are not limited to e.g., B-cell Acute Lymphoid Leukemia ("B-ALL"), T-cell Acute Lymphoid Leukemia ("T-ALL"), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Chronic Lymphoid Leukemia (CLL). Preferably, the leukemia is a relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia. Preferably, lymphomas include, but are not limited to Hodgkin's Disease, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Preferably, the lymphoma is a relapsed or refractory B-cell lymphoma.

[0043] In a preferred embodiment, the antibody that targets malignant B cells targets a B cell antigen described herein, including but not limited to, CD19, CD20, CD22, CD123, FLT-3, ROR-1, CD79a, CD79b, CD179b, CD10, or CD34.

[0044] Examples of antibodies that target malignant B cells include monoclonal, polyclonal, bi-specific antibodies, antibody conjugates (e.g., antibody-drug conjugates), or fragments thereof that target an antigen expressed on a malignant B cell, e.g., a malignant B cell antigen described herein, e.g., CD19, CD20, CD22, CD52, CD123, FLT-3, ROR-1, CD79a, CD79b, CD179b, CD10, or CD34. Preferably the antibodies that target malignant B cells include blinatumomab, rituximab,

ofatumumab, ocrelizumab, veltuzumab, obinutuzumab, moxetumomab pasudotox, TRU-015, AME133V, Pro131921ibritumomab tiuxetan, tositumumab

[0045] In a preferred embodiment, the antibody that targets malignant B cells targets (e.g., binds to) CD22. For example, in an embodiment the antibody that targets malignant B cells that targets CD22 includes: an anti-CD22 monoclonal antibody-MMAE conjugate (e.g., DCDT2980S); an scFv of an anti-CD22 antibody, e.g., an scFv of antibody RFB4; an scFv of an anti-CD22 antibody fused to all of or a fragment of Pseudomonas exotoxin-A (e.g., BL22); a humanized anti-CD22 monoclonal antibody (e.g., epratuzumab); the Fv portion of an anti-CD22 antibody, which is optionally covalently fused to all or a fragment or (e.g., a 38 KDa fragment of) Pseudomonas exotoxin-A (e.g., moxetumomab pasudotox); or an anti-CD19/CD22 bispecific antibody, optionally conjugated or linked to a toxin such as a deglycosylated ricin A chain. Preferably, the antibody that targets malignant B cells is conjugated or otherwise bound to a cytotoxic agent or a chemotherapeutic agent. Preferably the antibody that targets malignant B cells is conjugated or otherwise bound to a cytotoxic agent (e.g., calicheamicins, ozogamicin). Preferably the antibody that targets malignant B cells is a CD22-directed antibody-drug conjugate comprising a recombinant humanized immunoglobulin antibody specific for human CD22 (e.g., inotuzumab), a calicheamicin and a linker that attaches the calicheamicin to the inotuzumab. Most preferably the CD22-directed antibody-drug conjugate that targets malignant B cells is moxetumomab pasudox (Lumoxiti®) and inotuzumab ozogamicin (e.g., BESPONSA® (inotuzumab ozogamicin) for Injection).

Anti-cancer Therapy

[0046] In an embodiment, the CAR immunotherapy as described herein is administered to the subject before, during, simultaneously with or after, administration of the antibody that targets malignant B cells. Preferably, the CAR immunotherapy is administered to the subject before or after administration of the antibody that targets malignant B cells. Most preferably, the CAR immunotherapy is administered to the subject before administration of the antibody that targets malignant B cells.

[0047] The immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) that are engineered to express a CAR targeting malignant B cells and/or the antibody that targets malignant B cells are administered to the subject using methods known in the art. Preferably, the immune effector cells and/or the antibody are administered parenterally, e.g., subcutaneously, intraperitoneally, intramuscularly or intravenously.

[0048] In some preferred embodiments, the subject is pre-medicated with acetaminophen and an H-1 antihistamine prior to administration of the immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) that are engineered to express a CAR targeting malignant B cells.

[0049] In some preferred embodiments, the subject is pre-medicated with a corticosteroid, antipyretic and antihistamine prior to administration of the antibody that targets malignant B cells.

[0050] In some embodiments, the immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) that are engineered to express a CAR targeting malignant B cells are administered intravenously, e.g., as an intravenous infusion. For example, each infusion provides about 10^4 to 10^9 cells/kg body weight, in some instances 10^5 to 10^6 cells/kg body weight, including all integer values within those ranges. Immune effector cell compositions may also be administered multiple times at these dosages.

[0051] In some embodiments, the antibody that targets malignant B cells is administered intravenously, e.g., as an intravenous infusion. For example, each infusion provides about 0.1-2000 mg of the antibody that targets malignant B cells, including all integer values within this range. In some embodiments, the antibody that targets malignant B cells is administered at a dose of 0.01 mg/m² to 750 mg/m², including all integer values within this range. Preferably, each infusion provides about 0.5-1 mg/m², 0.8-10 mg/m², 10-100 mg/m², 150-175 mg/m², 175-200 mg/m², 200-225 mg/m², 225-250 mg/m², 250-300 mg/m², 300-325 mg/m², 325-350 mg/m², 350-375 mg/m², 375-400 mg/m², 400-425 mg/m², 425-450 mg/m², 450-475 mg/m², 475-500 mg/m², 500-525 mg/m², 525-550 mg/m², 550-575 mg/m², 575-600 mg/m², 600-625 mg/m², 625-650 mg/m², 650-675 mg/m², or 675-700 mg/m², where m² indicates the body surface area of the subject. In some embodiments, the antibody that targets malignant B cells is administered at a dosing interval of at least 4 days, e.g., 4, 7, 14, 21, 28, 35 days, or more. For example, the antibody that targets malignant B cells is administered at a dosing interval of at least 0.5 weeks, e.g., 0.5, 1, 2, 3, 4, 5, 6, 7, 8 weeks, or more. In some embodiments, the antibody that targets malignant B cells is administered at a dose and dosing interval described herein for a period of time, e.g., at least 2 weeks, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 weeks, or greater. For example, the antibody that targets malignant B cells is administered at a dose and dosing interval described herein for a total of at least 2 doses per treatment cycle (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more doses per treatment cycle). Preferably, the antibody that targets malignant B cells is inotuzumab ozogamicin dosed according to the following dosing regimes for Cycle 1 and subsequent cycles depending on the response to treatment:

5

	Day 1	Day 8	Day 15
Dosing regimen for Cycle 1			
All patients:			
Dose	0.8 mg/m ²	0.5 mg/m ²	0.5 mg/m ²
Cycle length	21 days ^a		
Dosing regimen for subsequent cycles depending on response to treatment			
Patients who have achieved a CR or CRi:			
Dose	0.5 mg/m ²	0.5 mg/m ²	0.5 mg/m ²
Cycle length	28 days		
Patients who have not achieved a CR or CRi:			
Dose	0.8 mg/m ²	0.5 mg/m ²	0.5 mg/m ²
Cycle length	28 days		

^a For patients who achieve a CR or a CRi, and/or to allow for recovery from toxicity, the cycle length may be extended up to 28 days (i.e., 7-day treatment-free interval starting on Day 21).

[0052] The cells expressing chimeric antigen receptors (CARs) that target malignant B cells can be administered before (i.e., prior to), during (i.e., at the same time) or after (i.e., subsequent to) administration of the antibodies that target malignant B cells. In a preferred embodiment, the cells expressing chimeric antigen receptors (CARs) that target malignant B cells are administered prior to administration of the antibodies that target malignant B cells. In one preferred embodiment, the cells expressing chimeric antigen receptors (CARs) that target malignant B cells are administered 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 18 hours, 20 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 14 days 28 days, or more,

prior to administration of the antibodies that target malignant B cells. Most preferably, the cells expressing chimeric antigen receptors (CARs) that target malignant B cells are administered 28 days prior to administration of the antibodies that target malignant B cells.

[0053] Doses of the immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) that are engineered to express a CAR targeting malignant B cells and/or the antibody that targets malignant B cells may be administered once, or more than once. In some embodiments, it is preferred that the immune effector cells are administered once (i.e., as a single administration) and the antibody is administered once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or seven times a week for a predetermined duration of time. The predetermined duration of time may be 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or up to 1 year or more.

[0054] In one embodiment, the methods of increasing or enhancing the efficacy of a CAR immunotherapy or the methods of treating a cancer (e.g., a B cell malignancy) comprise inhibiting the proliferation or reducing the population of cancer cells expressing a tumor antigen described herein, the methods comprising contacting a tumor antigen-expressing cancer cell population (e.g., a B cell malignancy) described herein with immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) that are engineered to express a CAR targeting malignant B cells in combination with an antibody that binds to a tumor antigen-expressing B cell described herein. In certain embodiments, the combination of the invention reduces the quantity, number, amount or percentage of cells and/or cancer cells by at least 25%, at least 30%, at least 40%, at least 50%, at least 65%, at least 75%, at least 85%, at least 95%, or at least 99% in a subject with a cancer associated with the expression of a tumor antigen as described herein, relative to a negative control. In one aspect, the cancer is a B cell malignancy, e.g., a hematologic cancer.

[0055] In preferred embodiments, the hematological cancer to be treated is chosen from a leukemia or a lymphoma. Preferably, leukemias include, but are not limited to e.g., B-cell Acute Lymphoid Leukemia ("B-ALL"), T-cell Acute Lymphoid Leukemia ("T-ALL"), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Chronic Lymphoid Leukemia (CLL). Preferably, the leukemia is a relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia. Preferably, lymphomas include, but are not limited to Large B-Cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Preferably, the lymphoma is a relapsed or refractory B-cell lymphoma.

[0056] In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule that targets malignant B cells described herein, are administered as a single, low dose which is not expected to provide any clinical benefit to the subject and the antibody that targets malignant B cells is administered at a dose that is not expected to result in complete remission (CR) of the cancer due to a high tumor burden at the time of dosing and/or poor physical condition of the subject.

[0057] The immune effector cells expressing a CAR molecule that targets B cells and the antibody that targets malignant B cells can target the same B cell antigen described herein or can target different B cell antigens described herein when used in combination. For example, the immune effector cells expressing a CAR molecule that targets a CD19 malignant B cell antigen can be used in combination with an antibody that targets a CD 19 malignant B cell antigen or with an antibody that targets a CD22 malignant B cell antigen.

[0058] In another embodiment, administration of an antibody that targets malignant B cells results in increased or prolonged proliferation of the CAR-expressing cells in a subject, e.g., as compared to a non-treated subject. In embodiments, increased proliferation is associated with an increase in the number of the CAR-expressing cells. In another embodiment, administration of an antibody that targets malignant B cells results in increased killing of cancer cells (e.g., malignant B cells) by the CAR-expressing cells in a subject, e.g., as compared to a non-treated subject.

[0059] In another embodiment, the subjects receive an infusion of the CAR-expressing cells and the antibody that targets malignant B cells described herein prior to transplantation, e.g., allogeneic stem cell transplant, of cells.

[0060] The dosages and treatment schedules of the above treatments to be administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. The scaling of dosages for human administration can be performed according to art-accepted practices.

Combination Therapies

[0061] The CAR-expressing cells that target malignant B cells in combination with the antibodies that target malignant B cells described herein may be used in further combination with other known agents and therapies.

[0062] The combination therapy described herein, e.g., immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) that are engineered to express one or more CARs targeting malignant B cells as described herein in combination with an antibody that binds to malignant B cells as described herein, can be administered in combination with at least one additional therapeutic agent.

In an embodiment, the at least one additional therapeutic agent can be administered before, simultaneously or after the combination therapy described herein, in the same or in separate compositions, or sequentially. For sequential administration, the CAR-expressing cell described herein and/or the antibody that targets B cells, can be administered first, and the additional
5 therapeutic agent can be administered second, or the order of administration can be reversed.

[0063] In another aspect of the present invention, kits that include one or more of the CAR-expressing cells that target malignant B cells and antibodies that target malignant B cells as disclosed herein are provided, whereby such kit may comprise a package insert or other labeling including directions for administration.

Pharmaceutical compositions

[0064] Pharmaceutical compositions of the present invention may comprise CAR-expressing cells, e.g., a plurality of CAR-expressing cells that target malignant B cells, as described herein, and/or antibodies that target malignant B cells, as described herein, in combination with one or
15 more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose, dextrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); human serum albumin, electrolytes (e.g.,
20 Plasma-Lyte A); and preservatives (e.g., Cryoserv® dimethylsulfoxide). Compositions of the present invention are in one aspect formulated for intravenous administration. Preferably, the CAR expressing cells that target malignant B cells are suspended in a patient-specific infusion bag and the antibody that targets malignant B cells is in the form of a lyophilized powder for reconstitution.

EXAMPLE

[0065] The invention is further described in detail by reference to the following experimental example. This example is provided for purposes of illustration only and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following example, but rather, should be construed to encompass any and all
30 variations which become evident as a result of the teaching provided herein.

[0066] Example 1:

[0067] The unexpected clinical result regards a male adult patient, age 27, diagnosed with acute lymphoblastic leukemia (ALL), who had undergone ten rounds of standard of care therapy from

which the patient had relapsed. This patient was subsequently qualified for enrollment into an experimental clinical phase-1/2a dose-escalating trial, studying the safety and efficacy of a single dose of CAR-modified T cells, designed to target the CD19 antigen, which is overexpressed on ALL cells and other B cell malignancies. The specific population of CAR-modified T cells used in this clinical trial is also known as a population of cytokine induced killer (CIK) cells, as defined by the concurrent expression of CD56 in a subpopulation of these T cells.

[0068] This patient was dosed with 1 million CAR-expressing T cells per kg body weight, which constitutes the lowest dose in this first-ever clinical trial, per regulatory approval. This dose was not expected to provide any clinical benefit to the patient, but would establish a first safety signal in humans. At the time of dosing with the CAR-modified T cells, the patient's bone marrow consisted of 60% blasts, which is considered to be a high amount of tumor burden, relative to the administered dose of CAR-expressing T cells.

[0069] The presence of the CAR-modified T cells in the patient's peripheral blood was monitored through measurement of vector copy numbers (VCN) using standard PCR methods.

Typically, therapeutic activity of CAR-modified T cells corresponds with proliferation and expansion of these T cells in the patient's peripheral blood, which coincides with increasing VCN levels. By Day 14 following the infusion of the CAR-modified T cells, the VCN count in this patient had peaked to a 4645 copies/mcg fold increase compared to Day 0. At Day 21 and day 28, the VCN count was reduced respectively to 221 copies/mcg and below level of quantification, and at day 28 the patient's blast count in the bone marrow had increased to 90%. Given these observations, the dose of CAR-modified T cells was not considered to have provided any clinical benefit to this patient. As this patient's tumor burden continued to expand, he received a single administration of 0.8mg/m² inotuzumab on Day 28, with the intent to control the rate of tumor growth.

[0070] Inotuzumab's therapeutic mechanism of action is able to facilitate tumor cell death.

However, the administered dose was not expected to result in a complete remission (CR), because of the high tumor burden at the time of dosing and the poor physical condition of the patient, which is believed to have a negative impact on the therapeutic efficacy of inotuzumab. On Day +1 after inotuzumab administration, this patient suffered from a significant cytokine release syndrome (CRS), which required admission to the intensive care unit (ICU).

[0071] CRS is not typically observed in patients receiving stand-alone inotuzumab therapy (see inotuzumab Package Insert). Instead, CRS is a clinical adverse event seen in correlation with CAR-modified T cell therapy, especially in patients carrying high tumor burden. Therefore, the life-threatening CRS in this patient was an unexpected severe adverse event (SAE), also because of the

perceived sub-therapeutic precedent dose of CAR-modified T cells and the absence of observed therapeutic effect of these cells, as measured by VCN and by the expanding tumor burden during the first 28 days after infusion of the CAR-modified T cells.

[0072] At Day +35, this patient was considered to have been in molecular CR, and remained stable in this condition for a subsequent 56 days, until he underwent an allogeneic bone marrow transplantation, with curative potential. At month 9 after infusion and month 5 after HSCT, the patient was still in molecular CR. Similar to the observed CRS, the clinical outcome of molecular CR was unexpected. On the other hand, molecular CR is often seen in patients treated with CAR-modified T cells as a stand-alone therapy, such as tisagenlecleucel, and is typically observed in conjunction with or following occurrence of CRS, where the intensity of CRS requires ICU admission of the patient.

[0073] The above described unexpected results support the hypothesis of a synergistic effect between inotuzumab and CAR-modified T cells, as these cells have shown the capacity to persist in the patients' peripheral blood for up to 70 days or longer. In this patient, inotuzumab was administered on Day 28 following infusion of the CAR-modified T cells, meaning that these cells could have been impacted by the administration of inotuzumab, thereby rendering them therapeutically active against the tumor cells.

[0074] The present invention relates to the design and preparation of polymeric hybrid core-shell nanocarriers of which the core is designed to bind transposons, transposases and/or plasmids and minicircles comprising transposon and/or transposases and the shell is designed to protect the payload, stabilize the nanocarrier, provide biocompatibility to the system, enable targeting to specific cells and tissue and promote efficient intracellular release of the payload from the nanocarrier.

CLAIMS

I/we claim:

1. A method of increasing or enhancing the efficacy of a CAR immunotherapy cancer treatment that targets malignant B cells in a subject in need thereof comprising administering to the subject an antibody that targets malignant B cells in combination with the CAR immunotherapy.
5
2. The method of claim 1 wherein the cancer is a hematological cancer.
3. The method of claim 1 wherein the CAR immunotherapy comprises immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) engineered to express a BCA CAR.
10
4. The method of claim 3 wherein the immune effector cells target CD19.
5. The method of claim 1 wherein the antibody that targets B cells is a humanized or human monoclonal antibody.
15
6. The method of claim 5 wherein the antibody is inotuzumab ozogamicin.
7. A method of treating a B cell malignancy in a subject in need thereof comprising administering to the subject an antibody that targets malignant B cells in combination with a CAR immunotherapy cancer treatment that targets malignant B cells.
20
8. The method of claim 7 wherein the cancer is a hematological cancer.
9. The method of claim 7 wherein the CAR immunotherapy comprises immune effector cells (e.g., T cells, NK cells, CIK cells) engineered to express a BCA CAR.
25

10. The method of claim 9 wherein the immune effector cells target CD19.

11. The method of claim 7 wherein the antibody that targets B cells is a humanized or human monoclonal antibody.

5

12. The method of claim 11 wherein the antibody is inotuzumab ozogamicin.

13. The methods of claims 1 or 7 wherein the cancer is selected from leukemias and lymphomas.

10 14. The methods of any of the above claims except claim 13 wherein the CAR immunotherapy cancer treatment comprises administration of a single, low dose of the immune effector cells which is not expected to provide any clinical benefit to the subject and the antibody is administered at a dose that is not expected to result in complete remission (CR) of the cancer due to a high tumor burden at the time of dosing and/or poor physical condition of the subject.

15

15. The methods of claim 13 wherein the leukemias are selected from B-cell Acute Lymphoid Leukemia ("B-ALL"), T-cell Acute Lymphoid Leukemia ("T-ALL"), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) and Chronic Lymphoid Leukemia (CLL).

20

15. The methods of claim 13 wherein the lymphomas are selected from Hodgkin's Disease, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

25

16. The methods of claim 13 wherein the CAR immunotherapy cancer treatment comprises administration of a single, low dose of the immune effector cells which is not expected to provide any clinical benefit to the subject and the antibody is administered at a dose that is not expected to

result in complete remission (CR) of the cancer due to a high tumor burden at the time of dosing and/or poor physical condition of the subject.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/18127

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C07K 14/705; C07K 14/725; C12N 5/0783; A61K 39/00; C07K 19/00; A61P 35/02 (2020.01)

CPC - C07K 14/7051; C12N 5/0636; C07K 2319/00; A61K 38/177; A61K 2039/505; A61P 35/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 2017/0226216 A1 (BLUEBIRD BIO, INC.) 10 August 2017 (10.08.2017) para [0004], [0008], [0091], [0094], [0360], [0369], [0379], [0386], [0387], [0405]	1-5, 7-11, 13, 14, 15A, 16 ----- 6, 12
Y	US 2016/0361360 A1 (IMMUNOMEDICS, INC.) 15 December 2016 (15.12.2016) para [0025]	6, 12

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 May 2020

Date of mailing of the international search report

02 JUL 2020

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Lee Young

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/18127

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
-----Go to Extra Sheet for continuation-----

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Claims 1-14, 15A, 16, limited to hematological cancer, B-cell Acute Lymphoid Leukemia (B-ALL)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US 20/18127

Continuation of Box III: Observations where Unity of Invention is lacking.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+: Claims 1-14, 15A, 15B, 16, drawn to a method of treatment comprising a CAR immunotherapy and an administered antibody that targets malignant B cells.

The method of treatment will be searched to the extent that the hematological cancer is the first named, leukemia (claim 13), B-cell Acute Lymphoid Leukemia (B-ALL)(claim 15A). It is believed that claims 1-14, 15A, 16 read on this first named invention and thus these claims will be searched without fee to the extent that they encompass the hematological cancer, B-ALL. Additional hematological cancers will be searched upon payment of additional fees. Applicant must specify the claims that encompass any additional elected hematological cancers. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined. An exemplary election would be: Non-Hodgkin's Lymphoma (claims 1-14, 15B, 16).

The inventions listed as Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Among the inventions listed as Groups I+ are the specific hematological cancers recited therein. Each invention requires a specific hematological cancer, not required by any other inventions.

Common Technical Features:

Group I+ inventions share the common technical feature of claims 1 and 7.

However, said common technical features do not represent a contribution over the prior art, and are disclosed by US 2017/0226216 A1 to Bluebird Bio, Inc. (hereinafter "Bluebird").

As to claim 1, Bluebird discloses a method of increasing or enhancing the efficacy of a CAR immunotherapy cancer treatment that targets malignant B cells in a subject in need thereof (para [0008]; "The invention generally provides improved vectors for generating T cell therapies and methods of using the same. More particularly, the invention provides humanized anti-BCMA CAR molecules and their use in treating, preventing, or ameliorating B cell related conditions") comprising administering to the subject an antibody that targets malignant B cells in combination with the CAR immunotherapy (para [0369]; "Illustrative examples of therapeutic antibodies suitable for combination with the CAR modified T cells contemplated herein, include but are not limited to ... inotuzumab" [targets the CD22 protein, which is produced in excess on the surface of most ALL [acute lymphocytic leukemia] cells]).

As to claim 7, Bluebird discloses a method of treating a B cell malignancy in a subject in need thereof comprising administering to the subject an antibody that targets malignant B cells (para [0369]) in combination with a CAR immunotherapy cancer treatment that targets malignant B cells (para [0008]).

As the common technical features were known in the art at the time of the invention, they cannot be considered common special technical features that would otherwise unify the groups. The inventions lack unity with one another.

Therefore, Groups I+ inventions lack unity of invention under PCT Rule 13 because they do not share a same or corresponding special technical feature.

Note concerning claim 15: The instant application has two claim 15s. For the purposes of this application, the claims are hereinafter referred to as claim 15A and claim 15B, respectively.